Literature DB >> 3668998

Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study.

J da Costa, J A Gomes, J Espirito Santo, M Queirós.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3668998

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  7 in total

1.  Raynaud's Phenomenon.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

Review 2.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

3.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

Review 4.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 5.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

Review 6.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 7.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.